OTCPK:CLVL.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore.


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Clinuvel Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLVL.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.6%

CLVL.F

-0.5%

US Biotechs

2.7%

US Market


1 Year Return

-33.8%

CLVL.F

26.8%

US Biotechs

9.1%

US Market

Return vs Industry: CLVL.F underperformed the US Biotechs industry which returned 26.8% over the past year.

Return vs Market: CLVL.F underperformed the US Market which returned 9.1% over the past year.


Shareholder returns

CLVL.FIndustryMarket
7 Day10.6%-0.5%2.7%
30 Day12.4%3.6%4.5%
90 Day57.4%14.2%2.3%
1 Year-33.8%-33.8%28.0%26.8%11.5%9.1%
3 Year210.5%210.5%33.7%29.3%30.6%22.0%
5 Year562.9%562.9%-3.1%-8.9%57.2%39.5%

Price Volatility Vs. Market

How volatile is Clinuvel Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Clinuvel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

77.6x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CLVL.F ($15.71) is trading above our estimate of fair value ($2.54)

Significantly Below Fair Value: CLVL.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CLVL.F is poor value based on its PE Ratio (77.6x) compared to the Biotechs industry average (18.6x).

PE vs Market: CLVL.F is poor value based on its PE Ratio (77.6x) compared to the US market (15.9x).


Price to Earnings Growth Ratio

PEG Ratio: CLVL.F is poor value based on its PEG Ratio (9.7x)


Price to Book Ratio

PB vs Industry: CLVL.F is overvalued based on its PB Ratio (20.2x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Clinuvel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

8.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLVL.F's forecast earnings growth (8% per year) is above the savings rate (2.2%).

Earnings vs Market: CLVL.F's earnings (8% per year) are forecast to grow slower than the US market (21.7% per year).

High Growth Earnings: CLVL.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: CLVL.F's revenue (23.4% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: CLVL.F's revenue (23.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLVL.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Clinuvel Pharmaceuticals performed over the past 5 years?

66.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLVL.F has high quality earnings.

Growing Profit Margin: CLVL.F's current net profit margins (47.2%) are lower than last year (57.9%).


Past Earnings Growth Analysis

Earnings Trend: CLVL.F has become profitable over the past 5 years, growing earnings by 66.7% per year.

Accelerating Growth: CLVL.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CLVL.F had negative earnings growth (-4.7%) over the past year, making it difficult to compare to the Biotechs industry average (-4.5%).


Return on Equity

High ROE: CLVL.F's Return on Equity (26.1%) is considered high.


Next Steps

Financial Health

How is Clinuvel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CLVL.F's short term assets (A$60.8M) exceed its short term liabilities (A$4.0M).

Long Term Liabilities: CLVL.F's short term assets (A$60.8M) exceed its long term liabilities (A$98.8K).


Debt to Equity History and Analysis

Debt Level: CLVL.F is debt free.

Reducing Debt: CLVL.F has not had any debt for past 5 years.

Debt Coverage: CLVL.F has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CLVL.F has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Clinuvel Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.10%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CLVL.F's dividend (0.1%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.69%).

High Dividend: CLVL.F's dividend (0.1%) is low compared to the top 25% of dividend payers in the US market (4.48%).


Stability and Growth of Payments

Stable Dividend: CLVL.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: CLVL.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CLVL.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLVL.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.3yrs

Average management tenure


CEO

Philippe Wolgen (56yo)

14.5yrs

Tenure

AU$1,415,126

Compensation

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group. ...


CEO Compensation Analysis

Compensation vs Market: Philippe's total compensation ($USD942.10K) is below average for companies of similar size in the US market ($USD3.20M).

Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Philippe Wolgen
CEO, MD & Director14.5yrsAU$1.42m7.09% A$56.5m
Darren Keamy
CFO & Company Secretary14.33yrsAU$336.50k0.62% A$4.9m
Dennis Wright
Acting Chief Scientific Officer7.67yrsAU$296.35k0.64% A$5.1m
Malcolm Bull
Head of Investor Relationsno datano datano data
Lachlan Hay
General Manager of Europeno datano datano data

14.3yrs

Average Tenure

Experienced Management: CLVL.F's management team is seasoned and experienced (14.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Philippe Wolgen
CEO, MD & Director14.5yrsAU$1.42m7.09% A$56.5m
Brenda Shanahan
Non-Executive Director13.17yrsAU$82.52k0.36% A$2.9m
Susan Smith
Non-Executive Director0.67yrno datano data
Jeffrey Rosenfeld
Non Executive Director0.50yrno data0.0034% A$27.3k
Willem Blijdorp
Non-Executive Chairman0.50yrAU$80.00k3.53% A$28.1m
Karen Agersborg
Non-Executive Director2.33yrsAU$65.00k0.011% A$88.7k

1.5yrs

Average Tenure

Experienced Board: CLVL.F's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Clinuvel Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinuvel Pharmaceuticals Limited
  • Ticker: CLVL.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$1.197b
  • Listing Market Cap: AU$796.697m
  • Shares outstanding: 49.41m
  • Website: https://www.clinuvel.com

Location

  • Clinuvel Pharmaceuticals Limited
  • 535 Bourke Street
  • Level 11
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UR9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2001
CUVASX (Australian Securities Exchange)YesOrdinary SharesAUAUDFeb 2001
CLVL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2001
CUVCHIA (Chi-X Australia)YesOrdinary SharesAUAUDFeb 2001
CLVL.YOTCPK (Pink Sheets LLC)SPON ADRUSUSDMay 2004
UR9ADB (Deutsche Boerse AG)SPON ADRDEEURMay 2004

Biography

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with erythropoietic protoporphyria in the People's Republic of China. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/30 04:05
End of Day Share Price2020/05/29 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.